1. Home
  2. VRNA vs LLYVK Comparison

VRNA vs LLYVK Comparison

Compare VRNA & LLYVK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRNA
  • LLYVK
  • Stock Information
  • Founded
  • VRNA 2005
  • LLYVK 1991
  • Country
  • VRNA United Kingdom
  • LLYVK United States
  • Employees
  • VRNA N/A
  • LLYVK N/A
  • Industry
  • VRNA Biotechnology: Pharmaceutical Preparations
  • LLYVK Broadcasting
  • Sector
  • VRNA Health Care
  • LLYVK Industrials
  • Exchange
  • VRNA Nasdaq
  • LLYVK Nasdaq
  • Market Cap
  • VRNA 8.3B
  • LLYVK 8.4B
  • IPO Year
  • VRNA 2017
  • LLYVK N/A
  • Fundamental
  • Price
  • VRNA $106.91
  • LLYVK $91.02
  • Analyst Decision
  • VRNA Buy
  • LLYVK
  • Analyst Count
  • VRNA 11
  • LLYVK 0
  • Target Price
  • VRNA $114.10
  • LLYVK N/A
  • AVG Volume (30 Days)
  • VRNA 1.5M
  • LLYVK 318.2K
  • Earning Date
  • VRNA 11-03-2025
  • LLYVK 01-01-0001
  • Dividend Yield
  • VRNA N/A
  • LLYVK N/A
  • EPS Growth
  • VRNA N/A
  • LLYVK N/A
  • EPS
  • VRNA N/A
  • LLYVK N/A
  • Revenue
  • VRNA $221,673,000.00
  • LLYVK N/A
  • Revenue This Year
  • VRNA $909.96
  • LLYVK N/A
  • Revenue Next Year
  • VRNA $76.47
  • LLYVK $11.45
  • P/E Ratio
  • VRNA N/A
  • LLYVK N/A
  • Revenue Growth
  • VRNA N/A
  • LLYVK N/A
  • 52 Week Low
  • VRNA $31.09
  • LLYVK $50.95
  • 52 Week High
  • VRNA $106.94
  • LLYVK $102.62
  • Technical
  • Relative Strength Index (RSI)
  • VRNA 72.60
  • LLYVK 38.24
  • Support Level
  • VRNA $105.78
  • LLYVK $88.95
  • Resistance Level
  • VRNA $106.86
  • LLYVK $98.52
  • Average True Range (ATR)
  • VRNA 0.16
  • LLYVK 2.33
  • MACD
  • VRNA -0.04
  • LLYVK -1.17
  • Stochastic Oscillator
  • VRNA 98.26
  • LLYVK 17.72

About VRNA Verona Pharma plc

Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.

About LLYVK Liberty Media Corporation

Liberty Live Group would be engaged in the operations of Live Nation, and Liberty Media's planning for that group is to maximize the value of its investment in that company and the other assets attributed to the Liberty Live Group and to use the new Liberty Live common stock to make strategic acquisitions or for other capital raising initiatives.

Share on Social Networks: